Mural Oncology (NASDAQ:MURA) Downgraded to “Equal Weight” Rating by Morgan Stanley

Morgan Stanley downgraded shares of Mural Oncology (NASDAQ:MURA) from an overweight rating to an equal weight rating in a report issued on Tuesday morning, Marketbeat.com reports.

A number of other brokerages also recently commented on MURA. Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research note on Wednesday, March 12th. Finally, Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Mural Oncology Trading Down 61.6 %

Mural Oncology stock opened at $1.47 on Tuesday. The stock has a 50 day moving average of $3.87 and a two-hundred day moving average of $3.61. Mural Oncology has a twelve month low of $1.37 and a twelve month high of $5.12. The stock has a market capitalization of $25.33 million, a price-to-earnings ratio of -0.16 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the previous year, the firm posted ($3.57) EPS. Equities analysts predict that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Trading of Mural Oncology

A number of institutional investors have recently bought and sold shares of MURA. Acorn Capital Advisors LLC purchased a new position in shares of Mural Oncology in the fourth quarter valued at $4,141,000. Renaissance Technologies LLC grew its stake in Mural Oncology by 17.4% in the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after acquiring an additional 35,403 shares during the last quarter. Geode Capital Management LLC increased its holdings in Mural Oncology by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares in the last quarter. Squarepoint Ops LLC raised its position in Mural Oncology by 1.4% during the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after acquiring an additional 2,470 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Mural Oncology in the third quarter valued at about $340,000. 80.21% of the stock is currently owned by hedge funds and other institutional investors.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.